Navigation Links
InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
Date:8/6/2008

BRITISH COLUMBIA, Canada, Aug. 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX VENTURE: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, today announced the addition of a new product designated DXLr120 (CD20). This is the third product added to the growing InNexus pipeline and was developed using new recombinant methods to produce a DXL(TM) anti CD20 antibody. InNexus' first and second products were developed with chemical methods to impart DXL(TM) into the development of new antibodies and the latest product represents a significant patent expansion for the company.

InNexus Chief Scientific Officer, Dr. Thomas Kindt, said, "Within the past two years, InNexus has moved rapidly to accelerate preclinical development of multiple candidates. Use of recombinant methods to develop DXLr120 with our patented DXL(TM) technology demonstrates the expertise of our team and the opportunity we have to create multiple therapeutic and diagnostic antibodies."

DXLr120 significantly improves antibodies binding to CD20, the target for Non Hodgkin's Lymphoma and Rheumatoid Arthritis and joins InNexus' well-studied DXL625 (CD20). DXL625, developed with chemical methods, also significantly improves the binding of antibodies to CD20 and increases potency using both in vitro and in vivo studies. Preliminary data for DXLr120 already reveals properties akin to those shown for DXL625. Plans are underway to subject DXLr120 to the full battery of tests for potency, in vivo efficacy and safety used for DXL625.

The company will present at IBC's 13th Annual World Congress Drug Discovery & Development of Innovative Therapeutics (DDT) Conference in Boston at the World Trade Center Boston. The InNexus presentation will be within the Main Conference (amphitheater) beginning at 9:40 AM (ET) on Wednesday, August 6th. Jeff Morhet, Chief Executive Officer and Dr. Thomas Kindt, Chief Scientific Officer will present an in-depth presentation of a Case Study of InNexus' preclinical candidate DXL625 (CD20): A New Platform for Augmenting Antibody Therapeutics for Cancer.

About Recombinant Antibodies

Antibodies are protein molecules produced by our immune system. The shape of an antibody is often described in a Y shape and one of their critical roles is to recognize and attack foreign bacteria and viruses. Antibodies come in numerous forms and each type can recognize unique antigen (targets). Each arm of the antibody (upper portion of the Y) has unique molecular structure (keys) that combine with the targets. Attachment of many antibodies to an object with these targets ultimately causes its destruction. Recombinant technologies have seen an explosion in use as manufacturing procedures have streamlined with shortened time frames and the final product often has a greater quality than that of products from non-recombinant methods.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
2. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
3. CuraGen to Present at The Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
4. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
5. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
7. BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
8. Genetic Engineering and Biotechnology News reports on early ADMET use
9. China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention
10. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
11. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology: